Virulence factors are components of pathogens that contribute to their ability to cause disease, and targeting these factors is a central strategy in vaccine development. Vaccines often aim to neutralize or block the action of virulence factors, such as bacterial toxins, surface proteins, or enzymes that enable pathogens to invade host cells or evade the immune system. By preventing the pathogen from expressing these harmful factors, vaccines can significantly reduce the severity of infection or prevent it altogether. For example, vaccines against bacterial diseases like tetanus, diphtheria, and whooping cough focus on neutralizing the toxins that cause damage in the body. Researchers continue to identify new virulence factors for targeting, especially for emerging or drug-resistant pathogens, expanding the range of diseases that can be controlled through vaccination. By focusing on virulence factors, vaccines can provide highly specific and effective protection with fewer side effects.
Khursheed Anwer
IMUNON, United States
Regina Au
BioMarketing Insight, United States
Madhu Khanna
University of Delhi, India
Khursheed Anwer
IMUNON, United States
Ping Xie
Rutgers University, United States
Regina Au
BioMarketing Insight, United States
Madhu Khanna
University of Delhi, India
Lara Isis Teodoro
Mayo Clinic, United States
Ahmed Abdulazeez
BHRUT Trust, United KingdomSubmit your abstract Today
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States
Title : Hypersensitivity and anti-SARS-COV-2 vaccination: A retrospective study of the year 2021 at the University Hospital Center of Tours (France)
Faure Quentin, The Savoie Metropolitan Hospital Center, France
Title : THE HPV vaccination program in Colombia. From a beautiful dream to a nightmare, but hopefully with a bright dawn.
Carlos Castro, Colombian League against cancer, Colombia